Li-Fraumeni syndrome (LFS) is a rare cancer predisposition syndrome usually associated with TP53 germline alterations. Its genetic basis in TP53 wild-type pedigrees is less understood. Using whole-genome sequencing, we identified a germline hemizygous deletion ablating CDKN2A-CDKN2B in a TP53 wild-type patient presenting with high-grade sarcoma, laryngeal squamous cell carcinoma and a family history suggestive of LFS. Patient-derived cells demonstrated reduced basal gene and protein expression of the CDKN2A-encoded tumour suppressors p14 ARF and p16 INK4A with concomitant decrease in p21 and faster cell proliferation, implying potential deregulation of p53-mediated cell cycle control. Review of 13 additional patients with pathogenic CDKN2A variants suggested associations of germline CDKN2A mutations with an expanded spectrum of non-melanoma familial cancers. To our knowledge, this is the first report of a germline gross deletion of the CDKN2A-CDKN2B locus in an LFS family. These findings highlight the potential contribution of germline CDKN2A deletions to cancer predisposition and the importance of interrogating the full extent of CDKN2A locus in clinical testing gene panels.
INTRODUCTION
Li-Fraumeni-like (LFL) syndrome is a variant of the Li-Fraumeni syndrome (LFS), a rare autosomal dominant cancer predisposition syndrome characterised by early onset of cancer and a broad tumour spectrum. 1 Patients with LFS/LFL typically present with characteristic LFS-associated tumours (soft-tissue sarcoma, osteosarcoma, breast cancer, brain tumour, leukaemia and adrenocortical carcinoma). The majority of these patients have germline mutations in TP53, a known susceptibility gene associated with LFS/LFL. 2 Studies have found that up to 20% of LFS 1, 2 and about 60% of LFL 3 families are wild-type for TP53. Germline alterations of other genes such as CHEK2 and CDKN2A in LFS/LFL families without TP53 mutations have been reported, but their role as susceptibility genes as yet remains controversial. 1, 2 Here we describe a specific patient presenting with both synchronous high-grade malignant peripheral nerve sheath tumour (MPNST) and head and neck squamous cell carcinoma (HNSCC). This patient met the diagnostic criteria 4 for LFS, but was wild-type for TP53. Additional sequencing and functional characterisation were performed to investigate other susceptibility genes potentially contributing to the cancers seen in this patient.
RESULTS

Case report
Patient is a 39-year-old male initially diagnosed with moderately differentiated laryngeal squamous cell carcinoma (SCC) with subglottic extension staged as T2N2bM0. Subsequent positron emission tomography (PET) scan revealed a soft-tissue mass adjacent to the right humeral head and another large mass in the left iliopsoas extending to the left inguinal and femoral region, which was diagnosed as grade III MPNST. Apart from tobacco usage, the patient had no remarkable personal or medical record suggestive of high-risk exposure to laryngeal SCC. As his clinical presentation, together with known family history, met the Chompret criteria 4 for LFS (Figure 1a ), clinical genetic testing was performed for TP53. No pathogenic sequence or copy-number changes were found. However, in this test, TP53 was part of a larger gene panel, which revealed a hemizygous deletion of all three p16
INK4A exons of CDKN2A. Given the absence of a personal or family history of melanoma, which might be expected in individuals with CDKN2A (specifically p16   INK4A ) mutations, we performed germline whole-genome sequencing (WGS) to further elucidate the basis for this patient's disease.
Whole-genome sequencing Copy-number analysis of the WGS data revealed a constitutional focal deletion on chromosome 9 of~270 kb, resulting in a hemizygous loss of the entire CDKN2A-CDKN2B locus and partially truncating the flanking MTAP and CDKN2B-AS genes (Figure 1b ). This region is homozygously deleted in the tumour, as seen by the near-loss of sequencing coverage in the MPNST tumour DNA (Figure 1b INK4A and p15 INK4B were represented by CDKN2A exon 1b, 1a and CDKN2B exon1, respectively. The reduced gene dosage ratio in patient germline and tumours (MPNST, laryngeal SCC) DNA compared with a pool of three healthy controls reflected the hemizgygous and homozygous loss of this locus. Each data point is a mean of quintuplicates with s.e. presented as error bars. P value was computed using Student's t-test. **P o0.01, ***P o0.001, ****P o0.0001. patient's germline and tumour DNA, demonstrating a gene dosage ratio of 0.5 and 0.0, respectively, compared with healthy controls (Figure 1c ). In addition, analysis of WGS data and PCR detection on the laryngeal SCC tumour (using PGMY-GP consensus primers, 5 data not shown) did not indicate ongoing human papillomavirus infection.
Molecular and functional analyses Hemizygous loss of CDKN2A could affect dosage of two tumour suppressor proteins encoded by the gene, p14 ARF and p16 INK4A . To investigate, we compared the endogenous messenger RNA and protein expression levels in lymphoblastoid cell lines (LCLs) derived from the patient versus healthy controls. Reverse transcription qPCR analysis confirmed that basal gene expression of p14 ARF and p16 INK4A was 50% lower than in healthy controls ( Figure 2a , P o 0.001 and P o0.01, respectively). Immunoblot analysis of these two proteins in the patient LCLs did not show such a significant decrease; however, it should be noted that the p14 ARF and p16 INK4A levels in the LCLs of healthy controls were variable ( Figure 2b) . Nevertheless, immunohistochemical analysis of both MPNST and laryngeal SCC tumours were clearly null for p14 ARF and p16 INK4A (Figure 2c) , consistent with the genomic loss observed by WGS (Figure 1b) .
A germline hemizygous loss of CDKN2A associated with lower endogenous p14 ARF suggests possible p14 ARF haploinsufficiency, which may affect p53-dependent cell cycle control even in the absence of a TP53 mutation in the patient. 6 The observed significantly higher rate of cell proliferation in the patient LCL supports the possibility of deregulated cell cycle control (Figure 2d ). To determine the potential consequences of reduced p14
ARF expression on the p53-dependent pathway, we investigated the expression levels of p53, MDM2 and one of the p53 downstream targets, p21. Whereas the messenger RNA and corresponding protein expression levels of MDM2 and p53 were inconsistent, p21 expression in the patient was significantly reduced at both messenger RNA and protein levels (Figures 2a and b) . Interestingly, while all three proteins were expressed in the laryngeal SCC tumour, MDM2 and p21 were not detectable in the MPNST (Figure 2e ).
DISCUSSION
To our knowledge, this is the first report of a hemizygous CDKN2A-CDKN2B germline deletion in an LFS/LFL family, where the proband presented with MPNST-HNSCC without a personal or family history of melanoma. The CDKN2A-CDKN2B locus encodes three tumour suppressor proteins-p14 ARF , p16   INK4A   and  p15 INK4B -all involved in cell cycle via p53 and retinoblastoma pathways.
7 p16 INK4A and p15 INK4B inhibit cyclin-dependent kinase (CDK)-mediated phosphorylation of retinoblastoma, thereby promoting G1 cell cycle arrest. 7 On the other hand, upon oncogenic stress, p14
ARF is induced and inhibits E3 ligase activity of MDM2 towards p53, thus leading to the stabilisation of p53 and activation of p53-mediated cell cycle arrest. As p14 ARF acts upstream of p53, it is conceivable that the germline hemizygous deletion of CDKN2A in our patient would phenocopy a hemizygous loss of TP53 in the impaired capacity for arresting cell proliferation. Indeed, it has been alluded that p14 ARF haploinsufficiency may predispose to tumour formation. 8 It has also been demonstrated that p14 ARF -null and p14 ARF -hemizygous mice are prone to earlier tumour development, especially of the sarcoma, lymphoma, carcinoma and neural system tumours spectrum, [9] [10] [11] but to our knowledge, this patient is the first human model that includes p14 ARF deficiency. The consistent observation of significantly reduced gene and protein expression of the p53 downstream target p21 in our patient LCL suggests the possible deregulation of p21 (Figures 2a and b) , supporting this hypothesis. We note the variability in protein expression among the LCLs of healthy controls, probably due to the variable effects of Epstein-Barr virus in the immortalisation of cell lines 12 and are thus interpreted with caution. However, the loss of p21 expression in the MPNST revealed by immunohistochemical analysis (Figure 2e ) further supports our hypothesis.
The complete genomic loss of the CDKN2A locus together with ablation of p14 ARF and p16 INK4A expression in both tumours (Figures 1b and 2c) is consistent with the observations in p14 ARF -hemizygous mice, whereby loss of the residual wild-type ARF was observed to accompany tumour development. 9 Interestingly, p21 and MDM2 were also undetectable in the MPNST with only p53 staining positive in the tumour, unlike the strong presence of all the three proteins in his laryngeal SCC. This differential protein expression between the patient's MPNST and laryngeal SCC tumours suggests the driving mechanisms in tumorigenesis of these tumours are potentially distinct. Presence of all three p53 pathway-associated proteins in the laryngeal SCC tumour suggests that tumorigenesis was probably less dependent on the p53 pathway and could potentially be more driven by deregulation in the retinoblastoma pathway associated with loss of p16
INK4A
. 13 In contrast, in the MPNST, expression of p21 appears to be abrogated even in the presence of p53 (Figure 2e ), suggesting deregulation of p21 potentially could be indirectly mediated by p14 ARF via other transcriptional factors in a p53-independent manner 14,15 and phenocopy LFS. Although it is known that p14 ARF predominantly inhibits MDM2 thereby stabilizing p53 and promoting its activation, 16 emerging body of evidences has shown that p14 ARF can interact with a host of proteins that may mediate the tumour suppressor activities of p14 ARF17 independent of p53. Germline mutations in CDKN2A are associated with familial melanoma and pancreatic cancer, and infrequently with neurofibroma, 18 HNSCC 19 and neural system tumours (astrocytoma and glioma). 20 To date, CDKN2A deletions have been reported in only a handful of kindreds displaying clustering of specific tumour spectrum, all of which feature melanoma: cutaneous malignant melanoma-neural system tumour, [20] [21] [22] melanoma-HNSCC, 19 melanoma-neurofibroma 18 and malignant melanoma. 23, 24 We reviewed the clinical records for a series of cancer patients who were found to be positive through gene Figure 2 . (a) Lower basal messenger RNA (mRNA) expression of CDKN2A and p53 pathway genes in LCL of the LFL patient (III-2) compared with a pool of three healthy controls. Fold change in mRNA was normalised against endogenous GAPDH and then compared against the mean of healthy controls. Each data point is a mean of triplicates with s.e. presented as error bars. P value was computed using Student's t-test. *Po 0.05, **Po 0.01, ***P o0.001, ****P o0.0001. INK4A . III and VI are tonsil and breast specimens, respectively, used as reference for positive control of the antibody staining. (d) Cell viability assay of the LFL patient compared against a pool of three healthy controls demonstrated significantly higher rate of cell proliferation. Assay was performed in quintuplicates. For healthy controls, LCLs from three healthy volunteers were used and the averaged value from these three lines were represented. Error bars: s.e. P value was computed using Student's t-test. *P o0.05. (e) Differential MDM2 and p21 expression profiles in MPNST and laryngeal SCC tumours. These two proteins were undetectable in MPNST but expressed in laryngeal SCC tumour, suggesting distinct mechanisms potentially involved in tumorigenesis of the two tumours. However, p53 expression was observed in both tumours. (I-III) MPNST; (IV-VI) laryngeal SCC. (f) The tumour spectrum of additionally reviewed 13 patient cases with CDKN2A pathogenic/likely pathogenic variants presented in a lollipop schematic. The frequency of each phenotype is 1, unless indicated within the lollipop.
Deletion of CDKN2A-CDKN2B locus SH Chan et al panel testing for germline CDKN2A mutations to better understand the phenotypic and mutation spectrum. In this series, there were a total of 29 cancers reported among the 14 patients from 12 unique families with germline CDKN2A mutations. The most common cancer was melanoma occurring in seven patients followed by sarcoma, pancreatic and breast cancers each occurring in two patients (Figure 2f , Supplementary Table 1) . The overall average age at first cancer diagnosis was 34 years (age range 9-60 years) and the average age at diagnosis of first melanoma was 27 years. Three patients had a history of multiple melanomas and one developed pancreatic cancer 25 years after a melanoma diagnosis. One homozygous individual presented with Hodgkin's lymphoma at age 12 years and had family history of early-onset lymphoma, jaw tumours, pancreatic, breast and lung cancers. A family history that would suggest hereditary cancer risk was reported in 13 out of 14 patients. Importantly, 2 out of 14 patients met the Chompret criteria and 11 out of 14 reported a family history of cancers characteristic of LFS/LFL spectrum. A review by Baker et al. highlighted a rare contiguous deletion in chromosome 9p21.3 obliterating~25 genes including CDKN2A, CDKN2B and MTAP in a melanoma-prone family with additional tumour spectrum (neural system tumours, leukaemia, chondrosarcoma, pontomedullary PNET and cervical cancer), 25 supporting our findings that genetic alterations involving CDKN2A could potentially underlie hereditary predisposition to cancers beyond melanoma. In our patient with hemizygous germline deletion of CDKN2A, it is prudent to extend melanoma screening given the increased risk of melanoma in families with CDKN2A alterations.
Recent reports revealed that loss of MTAP, a gene flanking and frequently co-deleted with CDKN2A, can render cancer cells sensitive to PRMT5 inhibition, thus opening up opportunities to exploit this vulnerability for treating tumours with MTAP-CDKN2A co-deletion. 26 For affected individuals with large deletions involving CDKN2A and MTAP, such as our patient and the family described by Baker et al., 25 the possibility of targeting this PRMT5 dependence raises potential for therapeutic strategies.
Currently, not all clinical testing panels include the entire CDKN2A locus (encompassing both p14 ARF and p16 INK4A genes). Our study suggests the importance of interrogating the full extent of this locus as alterations to p14 ARF may account for a small subset of germline TP53 wild-type LFS/LFL cases and should be included in clinical testing gene panels.
In summary, our study highlights the contribution of CDKN2A germline deletion to cancer predisposition in LFS/LFL patients and expands the non-melanoma phenotypic spectrum of cancers associated with germline CDKN2A mutations. Clinicians should consider genetic testing, including the entire CDKN2A locus, in their patients with LFS/ LFL or those with personal history of sarcoma, and family history of cancers beyond the traditional spectrum of CDKN2A. To the best of our knowledge, this is also the first report of a human p14 ARF deficiency model, providing insights into the potential role of p14 ARF and deregulation of the p53 pathway in sarcoma tumour development.
MATERIALS AND METHODS
This study was approved by the SingHealth Centralised Institutional Review Board (IRB 2011/826/B). Signed informed consent was given by the patient.
Genetic analysis Clinical genetic testing was performed at Invitae as previously described. 27 WGS of patient genomic DNA purified from peripheral blood and MPNST tissue was performed on an Illumina Hiseq2000 (Illumina Inc., San Diego, CA, USA) to a mean coverage of 72 × , data analysed by in-house pipeline and deposited in the European Nucleotide Archive (accession no. PRJEB13761).
The genomic deletion was validated by qPCR. For detailed methods, refer to Supplementary Information. Functional studies LCLs established by Epstein-Barr virus immortalisation of peripheral blood mononuclear cells of patient and healthy volunteers were used for cell proliferation and expression studies. Cell proliferation was assessed by viability assay using the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, WI, USA), whereas gene expression was quantitated using messenger RNA extracted from LCLs by reverse transcription qPCR. Protein expression was assessed by immunoblotting of whole-cell lysates from LCLs. Detailed methods including reverse transcription qPCR primers and immunoblotting antibodies are described in Supplementary Information. Immunohistochemical analysis was performed on 2-μm-thick slides sectioned from patient tumours and scored by a pathologist.
Statistical analysis P values were computed using two-tailed Student's t-test and were not adjusted for multiple testing.
